The state must directly underwrite massive obesity drug liabilities when private insurers refuse the risk.
When commercial plans and traditional insurance models withdraw coverage due to astronomical healthcare costs, governments must step in to bypass the system and directly guarantee pharmaceutical revenues.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
To bypass statutory limitations and commercial insurance reluctance, the federal government stepped in to directly finance seniors' access to weight-loss medications.
The deferral of standard Medicare Part D billing models forced the federal government to directly underwrite and prolong a temporary bridge subsidy program.
A state Medicaid program is directly financing obesity coverage only through a federally negotiated, manufacturer-discounted model after standalone coverage collapsed at list price.
The deep intersection of direct presidential stock purchases and aggressive federal policy highlights how tightly coupled the state has become with the success of obesity manufacturers.
Because private commercial plans refused to participate in permanent coverage models due to costs, the federal government was forced to extend its direct transitional funding program.
The federal government is stepping in to directly subsidize and guarantee access to high-cost obesity therapies where traditional private insurance coverage has been denied.
Despite negotiated state pricing, the immense burden of long-term obesity treatment still leaves a massive, un-offset deficit for the government to absorb.